Pharmaceutical Business Intelligence

  • Uncover prior art in abandoned patent applications and expired patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 7,285,668

« Back to Dashboard

Which drugs does patent 7,285,668 protect, and when does it expire?

Patent 7,285,668 protects DEXILANT SOLUTAB and DEXILANT and is included in two NDAs. There have been two Paragraph IV challenges on Dexilant. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for DEXILANT SOLUTAB has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in seventeen countries.

Summary for Patent: 7,285,668

Title:Process for the crystallization of (R)- or (S)-lansoprazole
Abstract:The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0.degree. C. to about 35.degree. C. from a C.sub.1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.
Inventor(s): Hashimoto; Hideo (Kobe, JP), Urai; Tadashi (Kawanishi, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/432,798
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
Takeda Pharms Usa
CAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXYesNo7,285,668*PED► SubscribeY
Takeda Pharms Usa
CAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009RXYesYes7,285,668*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,285,668

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-367757Dec 01, 2000
PCT Information
PCT FiledNovember 30, 2001PCT Application Number:PCT/JP01/10462
PCT Publication Date:June 06, 2002PCT Publication Number: WO02/44167

International Patent Family for Patent: 7,285,668

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland214684► Subscribe
Poland362801► Subscribe
Norway326019► Subscribe
Cyprus1112347► Subscribe
Denmark1337525► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.